Numerous drugs can increase cardiac output, thereby improving tissue oxygen delivery, but often they do this at the expense of increasing myocardial oxygen demand. This 3 Reducing afterload with vasodilators increases cardiac output,4 but this approach is often limited by hypotension. Pharmacological enhancement of contractility and mechanical augmentation of stroke volume are the final means of treating acute heart failure. We review the non-digitalis positive inotropic drugs and temporary mechanical pumps that are useful for this purpose.
effects. 6 The haemodynamic effects are predictable from a knowledge of their activity at autonomic receptors (see table) . Response to catecholamine infusions may be limited by the reduction in P receptor density and function (down regulation) which occurs with chronic sympathetic stimulation. ' The defect in ,3 receptor responses has been attributed to a 30% increase in activity of the inhibitory form of the G regulatory protein acting on adenyl cyclase.8 DOPAMINE Dopamine is a naturally occurring sympathetic amine which is the endogenous precursor of noradrenaline. At low doses (<4 ,uglkg/min) dopamine predominantly activates dopamine 1 and dopamine 2 receptors, increasing renal plasma flow, the glomerular filtration rate, and sodium excretion. ,1 Receptors are stimulated at doses between 4 and 10 pug/kg/min, resulting in an increased heart rate and cardiac output. At doses greater than 10 ,ug/kglmin ao receptor activation leads to vasoconstriction and raised systemic and ventricular filling pressures, which may result in ischaemia. Dopamine is often used as the first choice for treating shock as it increases inotropy while also restoring perfusion pressure to vital organs. It is useful in low dosage for augmenting renal blood flow, particularly in combination with other agents. 9 Dopamine may preserve renal function in shock states when noradrenaline has been used to raise systemic pressure. ' Dopexamine is a synthetic catecholamine with pronounced 12 agonism (60 times as potent as dopamine), negligible 13 agonism, no a effects, significant dopamine 1 receptor activation (one third the potency of dopamine), and mild dopamine 2 receptor activation. 24 In addition, it is a potent reuptake inhibitor of neurally released catecholamines.
Cardiovascular responses to dopexamine infusion include increased heart rate and cardiac index. The increase in left ventricular contractility is less than that evoked by dobutamine, but there is a greater decline in systemic and pulmonary vascular resistance.25 Diastolic filling pressures fall and mean arterial pressure usually changes by less than 10%. Dopexamine augments renal blood flow with one third the potency of dopamine, but this effect declines at doses over 2 pg/kg/min. Overall dopexamine should be regarded as an inodilator with haemodynamic effects similar to those of the phosphodiesterase inhibitors. It is used as an alternative to dobutamine to increase cardiac output and produce vasodilation, particularly in the renal and mesenteric beds.
Newer agents
The search for inotropic drugs which enhance systemic flow and provide some degree of renal protection but lack undesirable vasoconstrictor effects has led to the development of several novel dopaminergic agents. Fenoldopam is a dopamine 1 receptor agonist with no a or 13 effects. It is 10 times more potent than dopamine at dopamine 1 receptors.32 It increases the cardiac index and produces dose dependent reductions in systemic vascular resistance and blood pressure.
Renal blood flow increases by 40%. Ibopamine is a compound which is metabolised to epinine, a dopamine 1 receptor agonist with some activity at a and 1 receptors. Overall it is a vasodilating mild positive inotrope.32
Orally effective sympathomimetic drugs include terbutaline, pirbuterol, prenalterol, TA-064, butopamine, ibopamine, and dopexamine. They have no current place in the treatment of acute heart failure. Colforsin Box A outlines the indications for intra-aortic balloon pump placement. Insertion usually occurs via the femoral artery and may be percutaneous or surgical. Balloon inflation may be triggered from the R wave of the electrocardiogram (to coincide with the peak of the T wave), from an arterial trace, or at an intrinsic set rate. Balloon inflation should occur at closure of the aortic valve that is, at the dicrotic notch. Premature inflation will increase impedance to left ventricular ejection. Delay in inflation will needlessly decrease diastolic augmentation. Automatic adjustment of inflation has been described. 59 Complications with intra-aortic balloon pumps are frequent and may be severe. Up to 36% of patients may suffer vascular complications.-0 Leg ischaemia is the most common and may require removal of the balloon and embolectomy. A greater incidence occurs in patients with diabetes, in peripheral vascular disease, and in women and possibly with percutaneous insertion.6' Arterial injury and aortic dissection occur in fewer than 5% of cases, though necropsy studies indicate that many instances of aortic dissection are not clinically recognised.6' Preventing thromboembolisation requires full anticoagulation and avoidance of balloon non-inflation. Thrombocytopenia and haemolysis may occur, and infectious complications are manifested in 1-3% of patients.6'
Ventricular assist devices
The intra-aortic balloon pump will not be effective in patients with a cardiac index below 1-4 1/m5/min. These patients may benefit from one of the mechanical pumps designed for short term use-the ventricular assist devices. These pumps have evolved directly from heart-lung bypass machines developed for cardiac surgery. They may be classified in several ways (box B The Abiomed BVS 5000, a biventricular support system, is the device most often used at this hospital (fig 2) . It is a gravity filled, pneumatically driven, external prosthetic ventricle with an electromechanical console. Gravity filling allows the ventricular rate to adjust to venous return, in a fill to empty mode, avoiding pulmonary-systemic imbalance when providing biventricular assist. The Abiomed was the first device to receive approval from the United States Food and Drug Administration for postcardiotomy ventricular dysfunction. Of 347 patients given support with this device, 93 survived to hospital discharge. 62 The Biomedicus Centrifugal Pump is an external vortex device providing non-pulsatile flow, utilising an electrically powered magnetic impeller. It is easy to apply, relatively cheap, and can provide high flow rates. Non-pulsatile pumps are rarely used for longer than -one to two weeks, usually after cardiotomy. A degree of success (31% survival greater than 30 days) was reported in 67 patients after placement in an emergency or cardiac arrest setting. 63 The Thoratec Pierce Donachy ventricular assist device is a paracorporeal pulsatile sac-type pump. The pumps lie on the abdominal wall. The Novacor device is an intracorporeal left ventricular assist device consisting of a one piece polyurethane sac and a pair of pusher plates. The pump is placed in front of the posterior rectus sheath. The Thermocardiosystems ventricular assist device is a pneumatically activated pusher plate intracorporeal pump. The device is placed between the left ventricular apex and ascending aorta.
ASSIST-DEVICES AND ARTIFICIAL HEARTS REGISTRY
A combined registry for the clinical use of ventricular assist devices and total artificial hearts was established in 1985. A recent report contained data on over 1500 patients."M Support was instituted for postcardiotomy cardiogenic shock in 965 patients, 433 (45%) of whom were weaned from support, but only 237 (25%) survived to hospital discharge. A total of 544 patients received circulatory support in conjunction with heart transplantation, of whom 189 received a total artificial heart. Of the patients allocated to receive transplants, 436 required support for haemodynamic deterioration before orthotopic transplantation and 108 were supported after transplantation. Only 328 (69%) patients supported before operation were actually given a transplant, of whom 217 (66%) survived to discharge. The Kaplan-Meier survival rate at two years in this group was 65%, which compares with 80% in patients given transplants who were not receiving mechanical support. However, the two year survival for patients requiring only univentricular support was 83%. The incidence of multiorgan failure was substantially higher in patients bridged with a total artificial heart.
Several It is the privilege of the rich to watch catastrophes from a balcony. Giraudoux.
As Africa emerges from the "lost decade" of the 1980s it seems to be plunging into an even deeper quagmire of debt, ecological devastation, drought, and disease. Meanwhile we in the North watch the catastrophe, safe on our balconies, apparently unaware that our actions, and those of the institutions who represent us, are a major contributing factor to the continent's downward spiral of economic and social decline.
For years we have failed the ordinary people of Africa. Cast in the popular imagination of a bottomless pit for Westem charity, the reality is that Africa, despite its increasing poverty, now transfers to the rich North $10 billion a year, half of the debt interest due. Africa is not a lost cause: the people of Africa have shown resilience with a number of vibrant and innovative projects, communal associations, and small enterprises; they have struggled tenaciously to maintain their standards of living in the face of disasters. Africa can recover. What is required is urgent debt relief, fairer terms of trade, more democratic and transparent government, and economic programmes which are designed by and for African people rather than the rich in the North.
Malnutrition claims the lives of 11 000 children each day, and exposure to disease is heightened by the fact that two thirds of all Africans do not have access to clean water for cooking and drinking. Sub-Saharan African countries are currently spending 50% more on servicing their debt than on the health and education of their children2 and less now on health per capita than they did in 1980.3 As Africa's creditors, we should find this weighing heavily on our consciences. Despite paying out more than $1300 billion between 1982 and 1990, debtor countries are now 61% more indebted than they were in 1982. 4 How structural adjustment policies came about
The story of Africa has not always been one of doom and gloom. During the 1960s and 1970s progress in education and health care was impressive. African govemments consistently allocated a higher share of their gross national product to education and health than any other developing region except the Arab, states.3 The population with primary education doubled from 36% in 1960 to 79% in 1980. From a meagre total of 1000 university graduates in 1960, Africa was producing 70 600 graduates 29 years later. 3 Similar progress was made in health care, control of infectious diseases, hospitals, rural clinics, and community trained health workers. Child mortality more than halved between 1960 and 1990 (an achievement which took more than a century in the industrial world).5 The continent rode on a wave of hope.
